Oct 31, 2024 8:00am EDT Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Oct 23, 2024 8:45am EDT Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Oct 15, 2024 9:07am EDT Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
Sep 23, 2024 8:00am EDT Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
Aug 08, 2024 4:01pm EDT Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
Aug 07, 2024 9:31am EDT Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
Aug 05, 2024 8:00am EDT Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
Aug 01, 2024 8:00am EDT Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
Jul 10, 2024 8:30am EDT Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
